Stay updated on Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Sign up to get notified when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.

Latest updates to the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content removal regarding a clinical study on SARS-CoV-2, including details about hyper-inflammation and treatment options, while adding a new revision number and a specific EudraCT number for a study.SummaryDifference25%
- Check30 days agoChange DetectedThe web page has been updated from version v2.14.3 to v2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.